Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-124-NP
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Gene Therapies, Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-124-NP is a liposomal nanoparticle (LNP) formulation designed to deliver a plasmid DNA (pDNA) vector encoding microRNA-124 (miR-124). Developed by researchers at The University of Texas MD Anderson Cancer Center and Texas Tech University Health Sciences Center, this gene therapy aims to treat melanoma by inhibiting the Wnt/beta-catenin signaling pathway. miR-124 acts as a tumor suppressor that modulates the epithelial-mesenchymal transition (EMT) by decreasing the expression of SLUG, SNAIL, and vimentin. In preclinical murine models, intratumoral administration of miR-124-NP significantly reduced tumor burden and suppressed tumor growth by up to 50% without observed toxicity.
- Other names
- miR-124-loaded LNPsmiR124-loaded LNPsmiR 124-loaded LNPsliposomal nanoparticle-mediated miR-124 plasmid
Beyond the preview
Go deeper on miR-124-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-124-NP.